{
  "pmcid": "PMC4916189",
  "pmid": "26715213",
  "title": "Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Nai\u0308ve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study",
  "overall_score": 0.4934717979938501,
  "num_benchmarks": 3,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 17,
        "items": [
          {
            "variant": "rs3745274",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Across CYP2B6 516G>T genotypes, proportions with plasma viral load <200 copies/mL at week 96 were GG 238/243 (97.9%), GT 242/249 (97.2%), TT 52/54 (96.3%), Fisher\u2019s exact p=0.420, indicating no association with virological suppression.",
              "Sentence": "Genotypes GG, GT and TT are not associated with response to efavirenz in people with HIV Infections as compared to each other.",
              "Alleles": "GG, GT, TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other CYP2B6 516G>T genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "Table 3. Summary of the relationships between achieving plasma viral load <200 copies/mL at week 96 of therapy and single nucleotide polymorphisms (data analysed by Fisher\u2019s exact test)\n\nCYP2B6 516G>T\nGG 238/243 (97.9) 5/243 (2.1)\nGT 242/249 (97.2) 7/249 (2.8)\nTT 52/54 (96.3) 2/54 (3.7)\np-Value 0.420"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs3745274",
                "variant_id": "PA166155409",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs28399499",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "rs28399499",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "For CYP2B6 983T>C, virological suppression rates at week 96 were TT 500/513 (97.5%) and TC/CC 33/33 (100%), p=1.000, showing no significant association with plasma viral load <200 copies/mL.",
              "Sentence": "Genotypes TT and TC + CC are not associated with response to efavirenz in patients with HIV Infections as compared to each other.",
              "Alleles": "TT, TC + CC",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other CYP2B6 983T>C genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).\"",
                "\"CYP2B6 983T>C |  |  |  |\n| TT | 500/513 (97.5) | 13/513 (2.5) | 1.000 |\n| TC/CC | 33/33 (100) | 0/33 (0.0) |   |\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs4803419",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "rs4803419",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "For CYP2B6 15582C>T, suppression rates were CC 294/301 (97.7%) vs CT/TT 238/244 (97.5%), p=1.000, indicating no association with virological response.",
              "Sentence": "Genotypes CC and CT + TT are not associated with response to efavirenz in patients with HIV Infections as compared to each other.",
              "Alleles": "CC, CT + TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other CYP2B6 15582C>T genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "**Table 3. Summary of the relationships between achieving plasma viral load <200 copies/mL at week 96 of therapy and single nucleotide polymorphisms (data analysed by Fisher\u2019s exact test)**\n...\n\"CYP2B6 15582C>T\nCC 294/301 (97.7) 7/301 (2.3)\nCT/TT 238/244 (97.5) 6/244 (2.5)\np = 1.000\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4803419",
                "variant_id": "PA166155420",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs8192726",
            "gene": "CYP2A6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "rs8192726",
              "Gene": "CYP2A6",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "For CYP2A6*9B (rs8192726), CC 440/450 (97.8%) vs CA/AA 89/92 (96.7%) achieved plasma viral load <200 copies/mL at week 96, p=0.470, showing no significant effect on virological control.",
              "Sentence": "Genotypes CC and CA + AA are not associated with response to efavirenz in patients with HIV Infections as compared to each other.",
              "Alleles": "CC, CA + AA",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other CYP2A6*9B genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "CYP2A6*9B |  |  |  |\n| CC | 440/450 (97.8) | 10/450 (2.2) | 0.470 |\n| CA/AA | 89/92 (96.7) | 3/92 (3.3) |   |",
                "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs8192726",
                "variant_id": "PA166155447",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs28399454",
            "gene": "CYP2A6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "rs28399454",
              "Gene": "CYP2A6",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "For CYP2A6*17 (rs28399454), suppression rates were CC 477/488 (97.7%) and CT/TT 54/56 (96.4%), p=0.634, indicating no association with virological efficacy.",
              "Sentence": "Genotypes CC and CT + TT are not associated with response to efavirenz in patients with HIV Infections as compared to each other.",
              "Alleles": "CC, CT + TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other CYP2A6*17 genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "CYP2A6*17 |  |  |  |\n| CC | 477/488 (97.7) | 11/488 (2.3) | 0.634 |\n| CT/TT | 54/56 (96.4) | 2/56 (3.6) |   |",
                "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399454",
                "variant_id": "PA166155475",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs2307424",
            "gene": "NR1I3",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "rs2307424",
              "Gene": "NR1I3",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "For NR1I3 540C>T, week-96 suppression rates were CC 258/265 (97.4%), CT 192/198 (97.0%), TT 83/83 (100%), p=0.324, showing no significant association with viral suppression.",
              "Sentence": "Genotypes CC, CT and TT are not associated with response to efavirenz in patients with HIV Infections as compared to each other.",
              "Alleles": "CC, CT, TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other NR1I3 540C>T genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "NR1I3 540C>T |  |  |  |\n| CC | 258/265 (97.4) | 7/265 (2.6) | 0.324 |\n| CT | 192/198 (97.0) | 6/198 (3.0) |   |\n| TT | 83/83 (100) | 0/83 (0.0) |   |",
                "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs2307424",
                "variant_id": "PA166153700",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs3003596",
            "gene": "NR1I3",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "rs3003596",
              "Gene": "NR1I3",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "For NR1I3 1089T>C, suppression rates were TT 140/143 (97.9%), TC 258/266 (97.0%), CC 135/137 (98.5%), p=0.718, indicating no virological association.",
              "Sentence": "Genotypes TT, TC and CC are not associated with response to efavirenz in patients with HIV Infections as compared to each other.",
              "Alleles": "TT, TC, CC",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other NR1I3 1089T>C genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "NR1I3 1089T>C |  |  |  |\n| TT | 140/143 (97.9) | 3/143 (2.1) | 0.718 |\n| TC | 258/266 (97.0) | 8/266 (3.0) |   |\n| CC | 135/137 (98.5) | 2/137 (1.5) |   |",
                "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs3003596",
                "variant_id": "PA166153729",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs35599367",
            "gene": "CYP3A4",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "rs35599367",
              "Gene": "CYP3A4",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "For CYP3A4*22 (rs35599367), GG 506/518 (97.7%) vs GA 26/27 (96.3%) achieved pVL <200 copies/mL at week 96, p=0.487, suggesting no effect on virological outcome.",
              "Sentence": "Genotypes GG and GA are not associated with response to efavirenz in patients with HIV Infections as compared to each other.",
              "Alleles": "GG, GA",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other CYP3A4*22 genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).\"",
                "\"CYP3A4*22 |  |  |  |\n| GG | 506/518 (97.7) | 12/518 (2.3) | 0.487 |\n| GA | 26/27 (96.3) | 1/27 (3.7) |   |\"",
                "\"Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs35599367",
                "variant_id": "PA166157487",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs1045642",
            "gene": "ABCB1",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "rs1045642",
              "Gene": "ABCB1",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "For ABCB1 3435C>T, week-96 suppression rates were CC 232/239 (97.1%), CT 227/232 (97.8%), TT 74/75 (98.7%), p=0.797, indicating no association with virological efficacy.",
              "Sentence": "Genotypes CC, CT and TT are not associated with response to efavirenz in patients with HIV Infections as compared to each other.",
              "Alleles": "CC, CT, TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other ABCB1 3435C>T genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Additionally, ABCB1 3435C>T (rs1045642), NR1I2 63396C>T (rs2472677) and NR1I2 7635A>G (rs6785049) were genotyped using real-time PCR allelic discrimination assays for the present analysis (C_7586657_20, C26079845_10 and C_29280426_10, respectively; Applied Biosystems, Foster City, CA, USA), as previously described [8, 9].\"",
                "\"None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).\"",
                "\"ABCB1 3435C>T  CC 232/239 (97.1) 7/239 (2.9) p = 0.797; CT 227/232 (97.8) 5/232 (2.2); TT 74/75 (98.7) 1/75 (1.3).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1045642",
                "variant_id": "PA166157284",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs2472677",
            "gene": "NR1I2",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "rs2472677",
              "Gene": "NR1I2",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "For NR1I2 63396C>T, suppression rates were CC 135/139 (97.1%), CT 269/277 (97.1%), TT 126/127 (99.2%), p=0.462, showing no significant effect on achieving pVL <200 copies/mL.",
              "Sentence": "Genotypes CC, CT and TT are not associated with response to efavirenz in patients with HIV Infections as compared to each other.",
              "Alleles": "CC, CT, TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other NR1I2 63396C>T genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "NR1I2 63396 C>T\nCC | 135/139 (97.1) | 4/139 (2.9) | 0.462  \nCT | 269/277 (97.1) | 8/277 (2.9) |   \nTT | 126/127 (99.2) | 1/127 (0.8) |  ",
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs2472677",
                "variant_id": "PA166156358",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs6785049",
            "gene": "NR1I2",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 11,
              "Variant/Haplotypes": "rs6785049",
              "Gene": "NR1I2",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "For NR1I2 7635A>G, suppression rates were GG 283/292 (96.9%), GA 183/186 (98.4%), AA 64/65 (98.5%), p=0.610, indicating no association with virological response.",
              "Sentence": "Genotypes GG, GA and AA are not associated with response to efavirenz in patients with HIV Infections as compared to each other.",
              "Alleles": "GG, GA, AA",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "other NR1I2 7635A>G genotypes",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Additionally, ABCB1 3435C>T (rs1045642), NR1I2 63396C>T (rs2472677) and NR1I2 7635A>G (rs6785049) were genotyped using real-time PCR allelic discrimination assays for the present analysis (C_7586657_20, C26079845_10 and C_29280426_10, respectively; Applied Biosystems, Foster City, CA, USA), as previously described [8, 9].\"",
                "\"None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table 3).\"",
                "\"NR1I2 7635A>G  \nGG 283/292 (96.9) 9/292 (3.1) 0.610  \nGA 183/186 (98.4) 3/186 (1.6)   \nAA 64/65 (98.5) 1/65 (1.5)\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs6785049",
                "variant_id": "PA166156411",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs28399499",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 12,
              "Variant/Haplotypes": "rs28399499",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "CYP2B6 983TC or CC carriers had a decreased risk of CNS adverse events (Stocrin\u00ae product information definition) compared with TT homozygotes; multivariable logistic regression OR 0.30 (95% CI 0.12\u20130.75), p=0.010, indicating about 70% lower risk.",
              "Sentence": "Genotypes TC + CC are associated with decreased CNS adverse events related to efavirenz in patients with HIV Infections as compared to genotype TT.",
              "Alleles": "TC + CC",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "CNS adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % confidence interval [CI] 0.15\u20130.81, p = 0.015) and higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02\u20132.09, p = 0.040; OR 2.31, 95 % CI 1.33\u20134.02, p = 0.003, respectively).\"",
                "\"A decreased risk of CNS adverse events (Stocrin\u00ae product information) was associated with CYP2B6 983TC or CC carriers (OR 0.30, 95 % CI 0.12\u20130.75, p = 0.010) but an increased risk in patients with CYP2B6 15582CT or TT and ABCB1 3435TT carriers was observed (OR 1.59, 95 % CI 1.11\u20132.27, p = 0.011; and OR 2.14, 95 % CI 1.25\u20133.67, p = 0.006, respectively).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs4803419",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 13,
              "Variant/Haplotypes": "rs4803419",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Carriers of CYP2B6 15582CT or TT genotypes had an increased risk of CNS adverse events compared with CC homozygotes; multivariable logistic regression OR 1.59 (95% CI 1.11\u20132.27), p=0.011, corresponding to about a 59% higher risk.",
              "Sentence": "Genotypes CT + TT are associated with increased CNS adverse events related to efavirenz in patients with HIV Infections as compared to genotype CC.",
              "Alleles": "CT + TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "CNS adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15\u20130.81, p = 0.015) and higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02\u20132.09, p = 0.040; OR 2.31, 95 % CI 1.33\u20134.02, p = 0.003, respectively).\"",
                "\"A decreased risk of CNS adverse events (Stocrin\u00ae product information) was associated with CYP2B6 983TC or CC carriers (OR 0.30, 95 % CI 0.12\u20130.75, p = 0.010) but an increased risk in patients with CYP2B6 15582CT or TT and ABCB1 3435TT carriers was observed (OR 1.59, 95 % CI 1.11\u20132.27, p = 0.011; and OR 2.14, 95 % CI 1.25\u20133.67, p = 0.006, respectively).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4803419",
                "variant_id": "PA166155420",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs1045642",
            "gene": "ABCB1",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 14,
              "Variant/Haplotypes": "rs1045642",
              "Gene": "ABCB1",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "ABCB1 3435TT carriers had a higher risk of CNS adverse events than CC carriers; multivariable logistic regression OR 2.14 (95% CI 1.25\u20133.67), p=0.006, corresponding to approximately a 114\u2013131% increased risk.",
              "Sentence": "Genotype TT is associated with increased CNS adverse events related to efavirenz in patients with HIV Infections as compared to genotype CC.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "CNS adverse events related to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cA decreased risk of CNS adverse events (Stocrin\u00ae product information) was associated with CYP2B6 983TC or CC carriers (OR 0.30, 95 % CI 0.12\u20130.75, p = 0.010) but an increased risk in patients with CYP2B6 15582CT or TT and ABCB1 3435TT carriers was observed (OR 1.59, 95 % CI 1.11\u20132.27, p = 0.011; and OR 2.14, 95 % CI 1.25\u20133.67, p = 0.006, respectively).\u201d",
                "\u201cCNS adverse events were not driven by EFV dose or concentrations; however, CYP2B6 15582CT/TT and ABCB1 3435TT carriers were at higher risk (46 and 131 %, respectively) of CNS-related adverse events compared with 35 % lower risk in CYP2B6 983TC/CC patients.\u201d",
                "\u201cConversely, ABCB1 3435TT markedly increased the risk of experiencing CNS adverse events by 131 % compared with wild-type (CC).\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1045642",
                "variant_id": "PA166157284",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs3745274",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 15,
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Overall discontinuation of efavirenz (interruption >30 days) was more frequent in CYP2B6 516GT and TT carriers vs GG; multivariable Cox regression (model including NR1I2 63396) showed GT HR 1.80 (95% CI 1.01\u20133.21), p=0.047, and TT HR 2.66 (95% CI 1.26\u20135.60), p=0.010, indicating 80% and 166% increased risk of discontinuation.",
              "Sentence": "Genotypes GT and TT are associated with increased overall discontinuation of efavirenz in patients with HIV Infections as compared to genotype GG.",
              "Alleles": "GT, TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "overall discontinuation of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "GG",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively), whereas NR1I2 63396TT carriers were at decreased risk (22 %).",
                "Following adjustment for age, sex and dose, and stratifying by country, CYP2B6 516GT, TT and CYP2A6*9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively, whereas NR1I2 63396TT carriers had a 22 % reduced risk (Table [4](#Tab4)).",
                "CYP2B6 516G>T ... Multivariable Cox regressionb ... GG ... GT ... 0.047 1.80 1.01\u20133.21 ... TT ... 0.010 2.66 1.26\u20135.60"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs3745274",
                "variant_id": "PA166155409",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs8192726",
            "gene": "CYP2A6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 16,
              "Variant/Haplotypes": "rs8192726",
              "Gene": "CYP2A6",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "Patients with CYP2A6*9B CA or AA genotypes had higher risk of overall efavirenz discontinuation than CC; multivariable Cox HR 2.00 (95% CI 1.14\u20133.52), p=0.016, approximately doubling the risk.",
              "Sentence": "Genotypes CA + AA are associated with increased overall discontinuation of efavirenz in patients with HIV Infections as compared to genotype CC.",
              "Alleles": "CA + AA",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "overall discontinuation of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Following adjustment for age, sex and dose, and stratifying by country, *CYP2B6* 516GT, TT and *CYP2A6**9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively, whereas *NR1I2* 63396TT carriers had a 22 % reduced risk (Table [4](#Tab4)).",
                "*CYP2A6*9B |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| CC | 48 | 417 | 465 | 10.3 |   |   |   |   |   |   |   |   |   |\n| CA/AA | 19 | 85 | 104 | 18.3 | 0.024 | 1.85 | 1.09\u20133.14 | 0.012 | 1.98 | 1.16\u20133.38 | 0.016 | 2.00 | 1.14\u20133.52 |",
                "EFV concentrations influenced by metabolic and nuclear receptor polymorphisms but not dose were significantly associated with discontinuation. In contrast to the 48-week analysis, carriers of both *CYP2B6* 516GT or TT variants were at increased risk due to higher EFV concentrations, along with *CYP2A6**9B CA/AA."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs8192726",
                "variant_id": "PA166155447",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs2472677",
            "gene": "NR1I2",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 17,
              "Variant/Haplotypes": "rs2472677",
              "Gene": "NR1I2",
              "Drug(s)": "efavirenz",
              "PMID": 26715213,
              "Phenotype Category": "dosage",
              "Significance": "yes",
              "Notes": "NR1I2 63396TT carriers had a reduced risk of overall efavirenz discontinuation compared with CC; in multivariable Cox regression TT vs CC HR 0.22 (95% CI 0.07\u20130.67), p=0.008, corresponding to a 78% lower risk.",
              "Sentence": "Genotype TT is associated with decreased overall discontinuation of efavirenz in patients with HIV Infections as compared to genotype CC.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "overall discontinuation of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CC",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively), whereas NR1I2 63396TT carriers were at decreased risk (22 %).",
                "Following adjustment for age, sex and dose, and stratifying by country, CYP2B6 516GT, TT and CYP2A6*9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively, whereas NR1I2 63396TT carriers had a 22 % reduced risk (Table [4](#Tab4)).",
                "NR1I2 63396 C>T |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| CC | 23 | 126 | 149 | 15.4 | 0.008 |   |   | 0.006 |   |   | 0.018 |   |   |\n| CT | 40 | 252 | 292 | 13.7 | 0.635 | 0.88 | 0.53\u20131.48 | 0.666 | 0.89 | 0.53\u20131.49 | 0.970 | 1.01 | 0.59\u20131.72 |\n| TT | 4 | 125 | 129 | 3.1 | 0.002 | 0.19 | 0.07\u20130.54 | 0.002 | 0.18 | 0.06\u20130.52 | 0.008 | 0.22 | 0.07\u20130.67 |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs2472677",
                "variant_id": "PA166156358",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.8879882867137591,
      "total_samples": 8,
      "ground_truth_annotations": {
        "count": 8,
        "matched_count": 8,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.9721294283866883,
            "annotation": {
              "Variant/Haplotypes": "rs4803419",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Toxicity",
              "Alleles": "CT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Central Nervous System Disorder",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4803419",
                "prediction": "rs4803419",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CT + TT",
                "prediction": "15582CT/TT",
                "score": 0.9068434238433838,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Central Nervous System Disorder",
                "prediction": "Side Effect:CNS-related adverse events",
                "score": 0.9646214246749878,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC",
                "prediction": "15582CC",
                "score": 0.8498294353485107,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.9711554288864136,
            "annotation": {
              "Variant/Haplotypes": "rs28399499",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Toxicity",
              "Alleles": "CC + CT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Central Nervous System Disorder",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "TT"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs28399499",
                "prediction": "rs28399499",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CC + CT",
                "prediction": "983TC/CC",
                "score": 0.897243082523346,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Central Nervous System Disorder",
                "prediction": "Side Effect:CNS-related adverse events",
                "score": 0.9646214246749878,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "TT",
                "prediction": "983TT",
                "score": 0.849689781665802,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.963644129037857,
            "annotation": {
              "Variant/Haplotypes": "rs1045642",
              "Gene": "ABCB1",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Toxicity",
              "Alleles": "AA",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Central Nervous System Disorder",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "GG"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1045642",
                "prediction": "rs1045642",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "ABCB1",
                "prediction": "ABCB1",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "AA",
                "prediction": "3435TT",
                "score": 0.851146936416626,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Central Nervous System Disorder",
                "prediction": "Side Effect:CNS-related adverse events",
                "score": 0.9646214246749878,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "GG",
                "prediction": "3435CC",
                "score": 0.8206729292869568,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8672272682189941,
            "annotation": {
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Efficacy",
              "Alleles": "GT + TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Discontinuation",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "GG"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3745274",
                "prediction": "rs3745274",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "toxicity",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Alleles": {
                "ground_truth": "GT + TT",
                "prediction": "516GT and TT",
                "score": 0.9098619222640991,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Discontinuation",
                "prediction": "Side Effect:Overall efavirenz discontinuation",
                "score": 0.9076060056686401,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "GG",
                "prediction": "516GG",
                "score": 0.8548047542572021,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8566205739974976,
            "annotation": {
              "Variant/Haplotypes": "rs2472677",
              "Gene": "NR1I2",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Efficacy",
              "Alleles": "TT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Efficacy:Discontinuation",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "CC + CT"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs2472677",
                "prediction": "rs2472677",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "NR1I2",
                "prediction": "NR1I2",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "toxicity",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Alleles": {
                "ground_truth": "TT",
                "prediction": "63396TT",
                "score": 0.8441887497901917,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Discontinuation",
                "prediction": "Side Effect:Overall efavirenz discontinuation",
                "score": 0.9076060056686401,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "CC + CT",
                "prediction": "63396CC",
                "score": 0.8144109845161438,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8773376405239105,
            "annotation": {
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Efficacy",
              "Alleles": "T",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Phenotype": "Efficacy:virological response",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "G"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3745274",
                "prediction": "rs3745274",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "T",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:virological response",
                "prediction": "Efficacy:Plasma viral load <200 copies/mL at week 96",
                "score": 0.9226827025413513,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "G",
                "prediction": "516GG vs GT vs TT",
                "score": 0.8506937026977539,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.774257355928421,
            "annotation": {
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Efficacy",
              "Alleles": "T",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Phenotype": "Efficacy:virological response",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "G"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3745274",
                "prediction": "rs28399499",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "T",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:virological response",
                "prediction": "Efficacy:Plasma viral load <200 copies/mL at week 96",
                "score": 0.9226827025413513,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "G",
                "prediction": "983TT vs TC/CC",
                "score": 0.8198908567428589,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7741390824317932,
            "annotation": {
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "Phenotype Category": "Efficacy",
              "Alleles": "T",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Phenotype": "Efficacy:virological response",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "G"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs3745274",
                "prediction": "rs4803419",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2B6",
                "prediction": "CYP2B6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "efavirenz",
                "prediction": "efavirenz",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "T",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Not associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:virological response",
                "prediction": "Efficacy:Plasma viral load <200 copies/mL at week 96",
                "score": 0.9226827025413513,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "G",
                "prediction": "15582CC vs CT/TT",
                "score": 0.8187081217765808,
                "match_status": "partial_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 9,
        "items": [
          {
            "variant": "CYP2A6*9B",
            "gene": "CYP2A6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2A6*9B",
              "Gene": "CYP2A6",
              "Drug(s)": "efavirenz",
              "PMID": "26715213",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "CYP2A6*9B CA/AA carriers had increased risk of overall efavirenz discontinuation compared with CC (HR ~2.00, 95% CI 1.14\u20133.52, p=0.016).",
              "Sentence": "CYP2A6*9B is associated with increased risk of overall efavirenz discontinuation when treated with efavirenz in people with Disease:HIV infection.",
              "Alleles": "*9B CA/AA",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Overall efavirenz discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*9B CC",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26715213",
              "Variant Annotation ID_norm": "5",
              "Citations": [
                "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively), whereas NR1I2 63396TT carriers were at decreased risk (22 %).",
                "Following adjustment for age, sex and dose, and stratifying by country, CYP2B6 516GT, TT and CYP2A6*9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively, whereas NR1I2 63396TT carriers had a 22 % reduced risk (Table [4](#Tab4)).",
                "CYP2A6*9B |  |  |  |\n| CC | 48 | 417 | 465 | 10.3 |   |   |   |   |   |   |   |   |   |\n| CA/AA | 19 | 85 | 104 | 18.3 | 0.024 | 1.85 | 1.09\u20133.14 | 0.012 | 1.98 | 1.16\u20133.38 | 0.016 | 2.00 | 1.14\u20133.52 |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs3892097",
                "variant_id": "PA166156104",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "CYP2A6*9B",
            "gene": "CYP2A6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "CYP2A6*9B",
              "Gene": "CYP2A6",
              "Drug(s)": "efavirenz",
              "PMID": "26715213",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No association was observed between CYP2A6*9B and achieving plasma viral load <200 copies/mL at week 96 (p=0.470; 97.8% vs 96.7% suppressed for CC vs CA/AA).",
              "Sentence": "CYP2A6*9B is not associated with likelihood of achieving plasma viral load <200 copies/mL when treated with efavirenz in people with Disease:HIV infection.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Plasma viral load <200 copies/mL at week 96",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*9B CC vs CA/AA",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26715213",
              "Variant Annotation ID_norm": "10",
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "**CYP2A6*9B** |  |  |  |\n| CC | 440/450 (97.8) | 10/450 (2.2) | 0.470 |\n| CA/AA | 89/92 (96.7) | 3/92 (3.3) |   |",
                "Relationships between EFV PK parameters and single nucleotide polymorphisms (SNP; CYP2B6,CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) with plasma HIV-RNA (pVL) <200 copies/mL and EFV discontinuation and adverse events at 96 weeks were explored."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs3892097",
                "variant_id": "PA166156104",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "CYP2A6*17",
            "gene": "CYP2A6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 11,
              "Variant/Haplotypes": "CYP2A6*17",
              "Gene": "CYP2A6",
              "Drug(s)": "efavirenz",
              "PMID": "26715213",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No association was observed between CYP2A6*17 and achieving plasma viral load <200 copies/mL at week 96 (p=0.634; 97.7% vs 96.4% suppressed for CC vs CT/TT).",
              "Sentence": "CYP2A6*17 is not associated with likelihood of achieving plasma viral load <200 copies/mL when treated with efavirenz in people with Disease:HIV infection.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Plasma viral load <200 copies/mL at week 96",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*17 CC vs CT/TT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26715213",
              "Variant Annotation ID_norm": "11",
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "CYP2A6*17 |  |  |  |\n| CC | 477/488 (97.7) | 11/488 (2.3) | 0.634 |\n| CT/TT | 54/56 (96.4) | 2/56 (3.6) |   |",
                "Key Points table: \"Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2A6*17",
                "variant_id": "PA165924744",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs2307424",
            "gene": "NR1I3",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 12,
              "Variant/Haplotypes": "rs2307424",
              "Gene": "NR1I3",
              "Drug(s)": "efavirenz",
              "PMID": "26715213",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No association was observed between NR1I3 540C>T and achieving plasma viral load <200 copies/mL at week 96 (p=0.324; 97.4%, 97.0%, 100% suppressed for CC, CT, TT).",
              "Sentence": "NR1I3 rs2307424 is not associated with likelihood of achieving plasma viral load <200 copies/mL when treated with efavirenz in people with Disease:HIV infection.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Plasma viral load <200 copies/mL at week 96",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "540CC vs CT vs TT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26715213",
              "Variant Annotation ID_norm": "12",
              "Citations": [
                "\"Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed.\"",
                "\"None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).\"",
                "\"NR1I3 540C>T |  |  |  |\n| CC | 258/265 (97.4) | 7/265 (2.6) | 0.324 |\n| CT | 192/198 (97.0) | 6/198 (3.0) |   |\n| TT | 83/83 (100) | 0/83 (0.0) |   |\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs2307424",
                "variant_id": "PA166153700",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs3003596",
            "gene": "NR1I3",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 13,
              "Variant/Haplotypes": "rs3003596",
              "Gene": "NR1I3",
              "Drug(s)": "efavirenz",
              "PMID": "26715213",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No association was observed between NR1I3 1089T>C and achieving plasma viral load <200 copies/mL at week 96 (p=0.718).",
              "Sentence": "NR1I3 rs3003596 is not associated with likelihood of achieving plasma viral load <200 copies/mL when treated with efavirenz in people with Disease:HIV infection.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Plasma viral load <200 copies/mL at week 96",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "1089TT vs TC vs CC",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26715213",
              "Variant Annotation ID_norm": "13",
              "Citations": [
                "\"None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).\"",
                "\"NR1I3 1089T>C |  |  |  |\n| TT | 140/143 (97.9) | 3/143 (2.1) | 0.718 |\n| TC | 258/266 (97.0) | 8/266 (3.0) |   |\n| CC | 135/137 (98.5) | 2/137 (1.5) |   |\"",
                "\"Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs3003596",
                "variant_id": "PA166153729",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "CYP3A4*22",
            "gene": "CYP3A4",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 14,
              "Variant/Haplotypes": "CYP3A4*22",
              "Gene": "CYP3A4",
              "Drug(s)": "efavirenz",
              "PMID": "26715213",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No association was observed between CYP3A4*22 and achieving plasma viral load <200 copies/mL at week 96 (p=0.487; 97.7% vs 96.3% suppressed for GG vs GA).",
              "Sentence": "CYP3A4*22 is not associated with likelihood of achieving plasma viral load <200 copies/mL when treated with efavirenz in people with Disease:HIV infection.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Plasma viral load <200 copies/mL at week 96",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*22 GG vs GA",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26715213",
              "Variant Annotation ID_norm": "14",
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "CYP3A4*22 |  |  |  |\n| GG | 506/518 (97.7) | 12/518 (2.3) | 0.487 |\n| GA | 26/27 (96.3) | 1/27 (3.7) |   |",
                "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP3A4*22",
                "variant_id": "PA166048680",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs1045642",
            "gene": "ABCB1",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 15,
              "Variant/Haplotypes": "rs1045642",
              "Gene": "ABCB1",
              "Drug(s)": "efavirenz",
              "PMID": "26715213",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No association was observed between ABCB1 3435C>T and achieving plasma viral load <200 copies/mL at week 96 (p=0.797).",
              "Sentence": "ABCB1 rs1045642 is not associated with likelihood of achieving plasma viral load <200 copies/mL when treated with efavirenz in people with Disease:HIV infection.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Plasma viral load <200 copies/mL at week 96",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "3435CC vs CT vs TT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26715213",
              "Variant Annotation ID_norm": "15",
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "ABCB1 3435C>T |  |  |  |\n| CC | 232/239 (97.1) | 7/239 (2.9) | 0.797 |\n| CT | 227/232 (97.8) | 5/232 (2.2) |   |\n| TT | 74/75 (98.7) | 1/75 (1.3) |   |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1045642",
                "variant_id": "PA166157284",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs2472677",
            "gene": "NR1I2",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 16,
              "Variant/Haplotypes": "rs2472677",
              "Gene": "NR1I2",
              "Drug(s)": "efavirenz",
              "PMID": "26715213",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No association was observed between NR1I2 63396C>T and achieving plasma viral load <200 copies/mL at week 96 (p=0.462).",
              "Sentence": "NR1I2 rs2472677 is not associated with likelihood of achieving plasma viral load <200 copies/mL when treated with efavirenz in people with Disease:HIV infection.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Plasma viral load <200 copies/mL at week 96",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "63396CC vs CT vs TT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26715213",
              "Variant Annotation ID_norm": "16",
              "Citations": [
                "Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed.",
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "NR1I2 63396 C>T |  |  |  |\n| CC | 135/139 (97.1) | 4/139 (2.9) | 0.462 |\n| CT | 269/277 (97.1) | 8/277 (2.9) |   |\n| TT | 126/127 (99.2) | 1/127 (0.8) |   |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs2472677",
                "variant_id": "PA166156358",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs6785049",
            "gene": "NR1I2",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 17,
              "Variant/Haplotypes": "rs6785049",
              "Gene": "NR1I2",
              "Drug(s)": "efavirenz",
              "PMID": "26715213",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No association was observed between NR1I2 7635A>G and achieving plasma viral load <200 copies/mL at week 96 (p=0.610).",
              "Sentence": "NR1I2 rs6785049 is not associated with likelihood of achieving plasma viral load <200 copies/mL when treated with efavirenz in people with Disease:HIV infection.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Plasma viral load <200 copies/mL at week 96",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infection",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "7635GG vs GA vs AA",
              "Comparison Metabolizer types": null,
              "PMID_norm": "26715213",
              "Variant Annotation ID_norm": "17",
              "Citations": [
                "None of the SNPs assessed were associated with achieving pVL <200 copies/mL (Table [3](#Tab3)).",
                "NR1I2 7635A>G | GG | 283/292 (96.9) | 9/292 (3.1) | 0.610 | GA | 183/186 (98.4) | 3/186 (1.6) |   | AA | 64/65 (98.5) | 1/65 (1.5) |   | Table 3 Caption: Summary of the relationships between achieving plasma viral load <200 copies/mL at week 96 of therapy and single nucleotide polymorphisms (data analysed by Fisher\u2019s exact test).",
                "Key Points: \"Achieving pVL <200 copies/mL at 96 weeks was not associated with the selection of single nucleotide polymorphisms (SNP; CYP2B6, CYP2A6, CYP3A4, NR1I3, NR1I2, ABCB1) assessed.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs6785049",
                "variant_id": "PA166156411",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              }
            }
          }
        ]
      }
    },
    "study_parameters": {
      "score": 0.6419047619047619,
      "total_samples": 7,
      "ground_truth_annotations": {
        "count": 7,
        "matched_count": 7,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.7058823529411765,
            "annotation": {
              "Study Parameters ID": 1448993833,
              "Variant Annotation ID": 1448993831,
              "Study Type": "cohort, clinical trial",
              "Study Cases": 606.0,
              "Study Controls": null,
              "Characteristics": null,
              "Characteristics Type": "Unknown",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.006",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.14,
              "Confidence Interval Start": 1.25,
              "Confidence Interval Stop": 3.67,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448993833,
                "prediction": 4,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993831,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 606.0,
                "prediction": 606,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Treatment-na\u00efve HIV-infected adults: CNS-related adverse events in ABCB1 3435TT carriers versus ABCB1 3435CC while on efavirenz-based therapy to 96 weeks",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "disease",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.006",
                "prediction": "= 0.006",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.14,
                "prediction": 2.14,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.25,
                "prediction": 1.25,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.67,
                "prediction": 3.67,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7058823529411765,
            "annotation": {
              "Study Parameters ID": 1448993812,
              "Variant Annotation ID": 1448993810,
              "Study Type": "cohort, clinical trial",
              "Study Cases": 606.0,
              "Study Controls": null,
              "Characteristics": null,
              "Characteristics Type": "Unknown",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.01",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.3,
              "Confidence Interval Start": 0.12,
              "Confidence Interval Stop": 0.75,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448993812,
                "prediction": 2,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993810,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 606.0,
                "prediction": 606,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Treatment-na\u00efve HIV-infected adults: CNS-related adverse events in CYP2B6 983TC/CC carriers versus CYP2B6 983TT while on efavirenz-based therapy to 96 weeks",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "disease",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.01",
                "prediction": "= 0.010",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.3,
                "prediction": 0.3,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.12,
                "prediction": 0.12,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 0.75,
                "prediction": 0.75,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7058823529411765,
            "annotation": {
              "Study Parameters ID": 1448993822,
              "Variant Annotation ID": 1448993820,
              "Study Type": "cohort, clinical trial",
              "Study Cases": 606.0,
              "Study Controls": null,
              "Characteristics": null,
              "Characteristics Type": "Unknown",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.011",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.59,
              "Confidence Interval Start": 1.11,
              "Confidence Interval Stop": 2.27,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448993822,
                "prediction": 3,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993820,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 606.0,
                "prediction": 606,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Treatment-na\u00efve HIV-infected adults: CNS-related adverse events in CYP2B6 15582CT/TT carriers versus CYP2B6 15582CC while on efavirenz-based therapy to 96 weeks",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "disease",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.011",
                "prediction": "= 0.011",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.59,
                "prediction": 1.59,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.11,
                "prediction": 1.11,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.27,
                "prediction": 2.27,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5176470588235295,
            "annotation": {
              "Study Parameters ID": 1448993785,
              "Variant Annotation ID": 1448993783,
              "Study Type": "cohort, clinical trial",
              "Study Cases": 569.0,
              "Study Controls": null,
              "Characteristics": null,
              "Characteristics Type": "Unknown",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.016",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448993785,
                "prediction": 9,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993783,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 569.0,
                "prediction": 606,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Treatment-na\u00efve HIV-infected adults: stopping efavirenz due to EFV-related adverse events (clinician decision) in EFV600 versus EFV400 dose groups (multivariable Cox regression)",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "drug",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.016",
                "prediction": "= 0.016",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 2.54,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.19,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 5.43,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.4882352941176471,
            "annotation": {
              "Study Parameters ID": 1448993769,
              "Variant Annotation ID": 1448993767,
              "Study Type": "cohort, clinical trial",
              "Study Cases": 573.0,
              "Study Controls": null,
              "Characteristics": null,
              "Characteristics Type": "Unknown",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.01",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448993769,
                "prediction": 1,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993767,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 573.0,
                "prediction": 606,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Treatment-na\u00efve HIV-infected adults receiving efavirenz 400 mg or 600 mg once daily with tenofovir/emtricitabine; association of log-transformed EFV C12 with achieving plasma HIV RNA <200 copies/mL at 96 weeks",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "disease",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.01",
                "prediction": "= 0.204",
                "score": 0.5,
                "match_status": "partial_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 5.25,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.41,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 67.9,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.4588235294117647,
            "annotation": {
              "Study Parameters ID": 1448993796,
              "Variant Annotation ID": 1448993794,
              "Study Type": "cohort, clinical trial",
              "Study Cases": 570.0,
              "Study Controls": null,
              "Characteristics": null,
              "Characteristics Type": "Unknown",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.008",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448993796,
                "prediction": 8,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993794,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 570.0,
                "prediction": 606,
                "score": 0.8,
                "match_status": "partial_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Treatment-na\u00efve HIV-infected adults: overall efavirenz discontinuation in NR1I2 63396TT carriers versus NR1I2 63396CC (multivariable Cox regression adjusted for age, sex, dose and stratified by country)",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "disease",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.008",
                "prediction": "= 0.008",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.22,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.07,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.67,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.38235294117647056,
            "annotation": {
              "Study Parameters ID": 1448993766,
              "Variant Annotation ID": 1448993759,
              "Study Type": "cohort, clinical trial",
              "Study Cases": 546.0,
              "Study Controls": null,
              "Characteristics": null,
              "Characteristics Type": "Unknown",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.42",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Multiple groups"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448993766,
                "prediction": 5,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993759,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort, clinical trial",
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 546.0,
                "prediction": 606,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": null,
                "prediction": "Treatment-na\u00efve HIV-infected adults: overall efavirenz discontinuation in CYP2B6 516GT versus CYP2B6 516GG (multivariable Cox regression adjusted for age, sex, dose and stratified by country)",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics Type": {
                "ground_truth": "Unknown",
                "prediction": "disease",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.42",
                "prediction": "= 0.047",
                "score": 0.5,
                "match_status": "partial_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 1.8,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.01,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 3.21,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Multiple groups",
                "prediction": "Multiple Groups",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 2,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 6,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 606,
              "Study Controls": null,
              "Characteristics": "Treatment-na\u00efve HIV-infected adults: overall efavirenz discontinuation in CYP2B6 516TT versus CYP2B6 516GG (multivariable Cox regression adjusted for age, sex, dose and stratified by country)",
              "Characteristics Type": "disease",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.010",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 2.66,
              "Confidence Interval Start": 1.26,
              "Confidence Interval Stop": 5.6,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 7,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 606,
              "Study Controls": null,
              "Characteristics": "Treatment-na\u00efve HIV-infected adults: overall efavirenz discontinuation in CYP2A6*9B CA/AA carriers versus CYP2A6*9B CC (multivariable Cox regression adjusted for age, sex, dose and stratified by country)",
              "Characteristics Type": "disease",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.016",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 1.14,
              "Confidence Interval Stop": 3.52,
              "Biogeographical Groups": "Multiple Groups",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}